Within Stockholm Life Tech, we are currently working on developing the Life Science ecosystem at Campus Flemingsberg. And the first step in this process is a review of everything from academia to innovation support.
The Flemingsberg Science Foundation board approved its business plan for 2022 in January. This essentially paves the way for an increase in the pace of business set-ups and opportunities to innovate in Flemingsberg. Almost six months on, what have we achieved?
XNK Therapeutics has expanded significantly in the past year and now has access to its own GMP-standard production lab.
Hela is a company that is developing a mobile application that helps people with heart conditions improve their cardiac rehabilitation. The app encourages daily exercise, provides care support, and the ability to monitor progress.
Just before the pandemic, a research project was initiated in Tullinge in which residents were offered a place at a local work hub as an alternative to commuting to work. The hub is now seeing something of a reopening in a project aimed at increasing shared use and resource efficiency.
During the Kodkupan award evening in Flemingsberg, parents got to see the results of middle school students’ programming projects. Games and animations from the project were shown, prompting laughter and applause.
Nearly 100,000 people in Sweden suffer from Alzheimer’s. Globally, about 30 million people are thought to have the disease. There is still no cure, but research is approaching a point where new drugs may become crucial. AlzeCure is one of the pharmaceutical companies that has made the most progress.
“Cellaviva was founded by researchers from Karolinska Institutet, in the belief that stem cells will revolutionize how complex and incurable diseases are treated. We are a biobank that helps expectant parents to save stem cells from the umbilical cord at birth, in a so-called family bank. The aim is to make high-quality, potent cells available quickly, if medical needs arise. This creates treatment opportunities and expands therapy options for the whole family,”
NextCell Pharma in Flemingsberg has published extremely promising results from its clinical studies of drug candidate ProTrans for the treatment of type 1 diabetes. A study is now being carried out with the aim of examining its efficacy in children and young people.
Foundation Flemingsberg Science is to join the Swedish Incubators & Science Parks network, a collaboration that will accelerate the development of Flemingsberg’s internationally competitive innovation environment.